Experts outline treatment options for patients with venetoclax resistance.
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed the acalabrutinib 100mg tablets were bioequivalent to the acalabrutinib 100mg capsules.
Vaccine effectiveness against breakthrough SARS-CoV-2 infections was 10.5% for patients with lymphoma.
Zanubrutinib can improve progression-free survival, when compared with bendamustine-rituximab, in previously untreated CLL/SLL, a phase 3 trial suggests.
Researchers investigated a hypothesis that posttreatment bone marrow biopsy may not be needed after confirming complete response on imaging in patients with follicular lymphoma.
Zandelisib produced a high overall response rate in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.
Researchers sought to assess the importance of radiotherapy in pediatric patients with early‐stage low-risk classical Hodgkin lymphoma.
Mosunetuzumab produced an objective response rate of 80%.
Researchers sought to determine whether response-adapted sequential salvage therapy would be effective in patients with relapsed/refractory classical Hodgkin lymphoma.
Researchers sought to determine the trends in the utilization of Medicare on short-course radiotherapy in patients with lymphoma.
Tisagenlecleucel can produce responses in children and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma, a phase 2 study suggests.
Researchers sought to determine whether the combination pola-R-CHP would be cost-effective for treating patients with previously untreated DLBCL.
Researchers sought to determine the role and utilization of ASCT in younger patients with MCL.
Romidepsin is a histone deacetylase inhibitor indicated for the treatment of cutaneous T-cell lymphoma.
The researchers examined the prognostic significance of AMC and LMR in 316 patients with MALT lymphoma.
Obinutuzumab plus chemotherapy improved progression-free survival and time to next treatment.
The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.
Overall, there was no improvement in complete response or survival outcomes among patients who received bortezomib.
Male survivors of classical Hodgkin lymphoma had lower childbearing rates if they received BEACOPP rather than ABVD.
The safety profile remained similar to earlier analyses, with the most common grade 3 or higher adverse events including neutropenia and pneumonia.
Axi-cel improved event-free survival vs standard care in older patients with relapsed/refractory large B-cell lymphoma.
Researchers sought to determine whether adding pembrolizumab to consolidation chemotherapy would be effective in pediatric patients with high-risk classic Hodgkin lymphoma.
Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.
The 2 regimens produced similar efficacy outcomes, but adverse events were more common in the R-CODOX-M/R-IVAC arm.
Researchers sought to determine whether tislelizumab would be an effective treatment for patients with relapsed/refractory mature T/NK-cell lymphomas.
Researchers sough to determine whether zanubrutinib would improve responses compared with ibrutinib in patients with Waldenström macroglobulinemia.
Researchers sought to determine whether adding rituximab to axicabtagene ciloleucel would have efficacy in patients with refractory large B-cell lymphoma.
Researchers sought to determine whether evaluating circulating microRNAs in cerebrospinal fluid would be a sensitive approach for detecting secondary CNS involvement in B-NHL
Adding ibrutinib to standard chemoimmunotherapy improved the median progression-free survival by 2.3 years.
Researchers sought to define clinical and prognostic features associated with fever of unknown origin in patients later diagnosed with lymphoma.
Updated findings from the UNITY-CLL trial continue to show a possible increased risk of death among patients who received Ukoniq.
The accelerated approval for Kymriah was based on data from the phase 2 ELARA trial.
A study compared patients with diffuse large B-cell lymphoma with a 1:10 cohort from the general population to determine the risk of cardiovascular events in patients receiving doxorubicin-containing regimens.
Researchers sought to determine whether the GALEN regimen would yield favorable clinical outcomes in patients with previously untreated follicular lymphoma.
Researchers sought to determine whether tisagenlecleucel would be safe and effective in patients with primary central nervous system lymphoma.
Researchers sought to determine whether liso-cel would have acceptable toxicity and effectiveness in patients with SLL or CLL.
Researchers sought to determine whether patients with lymphoma receiving anticancer therapy had responses to COVID-19 vaccination.
The 1-year progression-free survival rate was 45%, and the 1-year overall survival rate was 59%.
Of the NHL patients with neutralizing antibodies against the WA1/2020 SARS-CoV-2 strain, 70% had antibodies against the delta variant, and 33% had antibodies against the omicron variant.
A phase 1 trial is currently evaluating the safety and tolerability of ADI-001 in 76 participants with B cell malignancies.
The decision to withdraw the pending applications was based on an intial review of data from the phase 3 UNITY-CLL trial.
The 5-year progression-free survival rate was significantly better in patients who underwent ASCT compared with those who did not.
Researchers sought to determine the optimal dosing for venetoclax in combination with ibrutinib for patients with relapsed or refractory MCL.
Researchers sought to develop a prognostic model for outcomes in pediatric patients with classical Hodgkin lymphoma based on gene expression data.
The approval was based on data from the phase 3 ZUMA-7 trial.
Researchers sought to determine whether a decision aid tool could help survivors of Hodgkin lymphoma understand lung cancer screening.
Researchers sought to develop a model to classify patients with diffuse large B-cell lymphoma into prognostic subgroups.
Bortezomib improved event-free survival and overall survival in children and young adults with T-cell lymphoblastic lymphoma.
Researchers sought to determine the dose and safety profile for mosunetuzumab administered for patients with aggressive and indolent relapsed or refractory B-NHLs.
Researchers sought to determine whether brentuximab vedotin with bendamustine would be effective in pediatric patients with relapsed or refractory Hodgkin lymphoma.
A retrospective study of patient data sought to determine if bone marrow infiltration is linked to adverse effect severity in patients with CD20-positive B-NHL.